Abstract | PURPOSE: PATIENTS AND METHODS:
Sunitinib- or sorafenib-treated cancer patients were vaccinated against seasonal influenza with an inactivated vaccine. Healthy controls and patients with metastatic renal cell cancer (mRCC) without systemic treatment (nontreated mRCC controls) were included for comparison. Antibody responses were measured at baseline, day 8, and day 22 by a standard hemagglutination inhibition assay and cellular T-cell responses at baseline and day 8 by proliferation assay and secretion of cytokines. RESULTS: Forty subjects were enrolled: 16 patients treated with sunitinib, 6 patients with sorafenib, 7 nontreated mRCC controls, and 11 healthy controls. All patients treated with sunitinib and sorafenib developed seroprotection rates comparable with controls. Functional T-cell reactivity was observed in all groups, except for patients treated with sorafenib who showed a decreased proliferation rate and IFN-γ/IL-2 production and increased IL-10 compared with healthy controls. CONCLUSION:
|
Authors | Sasja F Mulder, Joannes F M Jacobs, Michel A M Olde Nordkamp, Joep M D Galama, Ingrid M E Desar, Ruurd Torensma, Steven Teerenstra, Peter F A Mulders, Kris C P Vissers, Cornelis J A Punt, I Jolanda M de Vries, Carla M L van Herpen |
Journal | Clinical cancer research : an official journal of the American Association for Cancer Research
(Clin Cancer Res)
Vol. 17
Issue 13
Pg. 4541-9
(Jul 01 2011)
ISSN: 1557-3265 [Electronic] United States |
PMID | 21712444
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Benzenesulfonates
- Indoles
- Influenza Vaccines
- Phenylurea Compounds
- Pyridines
- Pyrroles
- Niacinamide
- Sorafenib
- Sunitinib
|
Topics |
- Adult
- Aged
- Antineoplastic Agents
(therapeutic use)
- Benzenesulfonates
(therapeutic use)
- Carcinoma, Renal Cell
(drug therapy, immunology)
- Female
- Humans
- Immunity, Cellular
(immunology)
- Immunity, Humoral
(immunology)
- Indoles
(therapeutic use)
- Influenza Vaccines
(immunology)
- Influenza, Human
(immunology, prevention & control)
- Kidney Neoplasms
(drug therapy, immunology)
- Male
- Middle Aged
- Niacinamide
(analogs & derivatives)
- Phenylurea Compounds
- Pyridines
(therapeutic use)
- Pyrroles
(therapeutic use)
- Sorafenib
- Sunitinib
- Time Factors
- Vaccination
|